Pathogenic link between chronic obstructive pulmonary disease and squamous cell lung cancer

Expert Review of Respiratory Medicine

Volumn 1, Issue 2, 2007, Pages 171-175

  Caramori, Gaetano ^a   Papi, Alberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67651189254     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.1.2.171     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA. Cancer J. Clin. 55 (2), 74–108 (2005).
2. Ben-Zaken O, Cohen S, Parè D et al. The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism. Am. J. Respir. Crit. Care Med. 176 (2), 113–120 (2007).
3. Mannino DM, Aguayo SM, Petty TL et al. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. Arch. Intern. Med. 163 (12), 1475–1480 (2003).
4. Anthonisen NR, Skeans MA, Wise RA et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 142 (4), 233–239 (2005).
5. Malhotra S, Lam S, Man SF et al. The relationship between stage 1 and 2 non-small cell lung cancer and lung function in men and women. BMC Pulm. Med. 6 (2), 1–6 (2006).
6. Papi A, Casoni G, Caramori G et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small-cell lung cancer. Thorax 59 (8), 679–681 (2004).
7. Janssen-Heijnen ML, Coebergh JW. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 31 (2–3), 123–137 (2001).
8. Carney DN. Lung cancer – time to move on from chemotherapy. N. Engl. J. Med. 346 (2), 126–128 (2002).
9. Zhang JJ, Smith KR. Household air pollution from coal and biomass fuels in china: measurements, health impacts, and interventions. Environ. Health Perspect. 115 (6), 848–855 (2007).
10. Turner MC, Chen Y, Krewski D et al. COPD associated with lung cancer mortality in a prospective study of never smokers. Am. J. Respir. Crit. Care Med. 176 (3), 285–290 (2007)
11. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking, 1955–1960 vs. 1970–1977. N. Engl. J. Med. 300 (24), 381–385 (1979).
12. Giangreco A, Groot KR, Janes SM. Lung cancer and lung stem cells: strange bedfellows? Am. J. Respir. Crit. Care Med. 175 (6), 547–553 (2007).
13. Sato A, Shames DS, Gazdar AF et al. A translational view of the molecular pathogenesis of lung cancer. J. Thorac. Oncol. 2 (4), 327–343 (2007).
14. Segal RA, Martonen TB, Kim CS et al. Computer simulations of particle deposition in the lungs of chronic obstructive pulmonary disease patients. Inhal. Toxicol. 14 (7), 705–720 (2002).
15. Zhang JY, Wang Y, Prakash C. Xenobiotic-metabolizing enzymes in human lung. Curr. Drug Metab. 7 (8), 939–948 (2006).
16. Caramori G, Adcock IM. Gene–environment interactions in the development of chronic obstructive pulmonary disease. Curr. Opin. Allergy Clin. Immunol. 6 (5), 323–338 (2006).
17. Popanda O, Edler L, Waas P et al. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer 55 (1), 25–34 (2007).
18. Lee YL, Chen W, Tsai WK et al. Polymorphisms of p53 and p21 genes in chronic obstructive pulmonary disease. J. Lab. Clin. Med. 147 (5), 228–233 (2006).
19. Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD 1 (1), 59–70 (2004).
20. Tomita K, Caramori G, Lim S et al. Increased p21CIP1/WAF1 and bcl-xL expression and reduced apoptosis in alveolar macrophages from smokers. Am. J. Respir. Crit. Care Med. 166 (3), 724–731 (2002).
21. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357 (9255), 539–545 (2001).
22. Ballaz S, Mulshine JL. The potential contributions of chronic inflammation to lung carcinogenesis. Clin. Lung Cancer 5 (1), 46–62 (2003).
23. Di Stefano A, Caramori G, Oates T et al. Increased expression of NF-κB in bronchial biopsies from smokers and patients with chronic obstructive pulmonary disease (COPD). Eur. Resp. J. 20 (3), 556–563 (2002).
24. Caramori G, Adcock IM, Ito K. Anti-inflammatory inhibitors of IκB kinase in asthma and COPD. Curr. Opin. Investig. Drugs 5 (11), 1141–1147 (2004).
25. Tang X, Liu D, Shishodia S et al. Nuclear factor-κB (NF-κB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107 (11), 2637–2646 (2006).
26. Greten FR, Karin M. The IKK/NF-κB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 206 (2), 193–199 (2004).
27. Denlinger CE, Keller MD, Mayo MW et al. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 127 (4), 1078–1086 (2004).
28. Rundall BK, Denlinger CE, Jones DR. Combined histone deacetylase and NF-κB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 136 (2), 416–425 (2004).
29. Carlisle DL, Liu X, Hopkins TM et al. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm. Pharmacol. Ther. (2006) (Epub ahead of print).
30. Tsurutani J, Castillo SS, Brognard J et al. Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells. Carcinogenesis 26 (7), 1182–1195 (2005).
31. Roman J, Ritzenthaler JD, Gil-Acosta A et al. Nicotine and fibronectin expression in lung fibroblasts: implications for tobacco-related lung tissue remodeling. FASEB J. 18 (12), 1436–1438 (2004).
32. Racke K, Matthiesen S. The airway cholinergic system: physiology and pharmacology. Pulm. Pharmacol. Ther. 17 (4), 181–198 (2004).
33. Song P, Sekhon HS, Proskocil B et al. Synthesis of acetylcholine by lung cancer. Life Sci. 72 (18–19), 2159–2168 (2003).
34. Pieper MP, Chaudhary NI, Park JE. Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide. Life Sci. 80 (24–25), 2270–2273 (2007).
35. Martinez-Moreno P, Nieto-Ceron S, Torres-Lanzas J et al. Cholinesterase activity of human lung tumours varies according to their histological classification. Carcinogenesis 27 (3), 429–436 (2006).
36. Psarras S, Caramori G, Contoli M et al. Oxidants in asthma and chronic obstructive pulmonary disease (COPD). Curr. Pharm. Des. 11 (6), 2053–2062 (2005).
37. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73, 39–85 (2004).
38. Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc. Am. Thorac. Soc. 3 (6), 535–537 (2006).
39. Popanda O, Schattenberg T, Phong T et al. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis 25 (12), 2433–2441 (2004).
40. Pierrou S, Broberg P, O’Donnell RA et al. Expression of genes involved in oxidative stress responses in airway epithelial cells of smokers with chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 175 (6), 577–586 (2007).
41. Fukumoto S, Yamauchi N, Moriguchi H et al. Overexpression of the aldo–keto reductase family protein AKR1B10 is highly correlated with smokers’ non-small cell lung carcinomas. Clin. Cancer Res. 11 (5), 1776–1785 (2005).
42. Ramalingam S, Belani CP. Recent advances in targeted therapy for non-small cell lung cancer. Expert Opin. Ther. Targets 11 (2), 245–257 (2007).
43. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, April 2001; NIH Publication No 2701:1–100. Last update 2006. www.goldcopd.com